Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Dasatinib (Sprycel) - Oncology Nurse Advisor
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | NEJM
SciELO - Brasil - Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET | Journal of Nuclear Medicine
Dasatinib (Sprycel) - Oncology Nurse Advisor
Scaffolds of Bosutinib, Dasatinib, amd Saracatinib, and their respective status in clinical trials.
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature | Haematologica
Dasatinib for Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial | Power
Dasatinib | Nature Reviews Drug Discovery
PDF) Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Dasatinib + Quercetin for Alzheimer Disease Clinical Trial | Power
![PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/40a02cde3eb975357a6d12781298237c9dc12611/2-Figure1-1.png "PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar")
PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar
![PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/40a02cde3eb975357a6d12781298237c9dc12611/6-Figure4-1.png "PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar")
PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar
Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML) - Clinical Trials Arena
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Leukemia
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment - ScienceDirect
Pyrvinium alone, and in combination with dasatinib, inhibits growth of... | Download Scientific Diagram
Efficacy of dasatinib and nilotinib in patients with CP CML harboring... | Download Table
Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis - Clinical Therapeutics
BUY dasatinib (SPRYCEL) 70 mg/1 E.R. Squibb & Sons, L.L.C.
Dasatinib - Wikipedia
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors - Cancer Treatment Reviews
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance | British Journal of Cancer
